Glen Deleavey, PhD Patent Agent in Training


Speaks:  English

Primary phone: +1 613-786-8659

Fax: +1 613-563-9869

Email: glen.deleavey@gowlingwlg.com

Download VCard


Primary office:  Ottawa


Areas of expertise:


Glen Deleavey, PhD

Dr. Glen Deleavey is a patent agent in training in Gowling WLG's Intellectual Property Group, based in the firm's Ottawa office. With his broad scientific background, Glen provides technical consulting, patent drafting, and patent prosecution services in a wide variety of scientific disciplines. He is also a member of Gowling WLG's Life Sciences Group.

Glen has an extensive background in chemistry and biochemistry. He obtained his PhD from the Department of Chemistry at McGill University. His graduate studies focused on the development of chemically modified nucleic acids and nucleoside analogues as potential therapeutics. Prior to his graduate studies, he completed his honours B.Sc. in biology-chemistry at the University of New Brunswick.

Glen was the recipient of research fellowships and awards during his studies, including the Vanier Canada Graduate Scholarship.

Career & Recognition

Filter timeline:
  • 2013

    • Education
      2013
      Ph.D. Chemistry, Chemical Biology Option, McGill University
  • 2009

    • Rankings & Awards
      2009
      Vanier Canada Graduate Scholarship, 2009-2012
  • 2007

    • Education
      2007
      Honours B.Sc. Biology-Chemistry, University of New Brunswick
  • 2005

    • Rankings & Awards
      2005
      Natural Sciences and Engineering Research Council of Canada (NSERC), various awards & fellowships, 2005-2009
    • Rankings & Awards
      Natural Sciences and Engineering Research Council of Canada (NSERC), various awards & fellowships, 2005-2009
    • Rankings & Awards
      Vanier Canada Graduate Scholarship, 2009-2012

ARTICLES PUBLISHED IN REFEREED JOURNALS:

  • Martín-Pintado, N., Deleavey, G. F., Portella, G., Campos-Olivas, R., Orozco, M., Damha, M. J., Gonzalez, C. Backbone FC-H…O hydrogen bonds in 2′F-substituted Nucleic Acids. Angew. Chemie. Int. Ed. doi: 10.1002/anie.201305710 (2013).
  • *Chan, D. P. Y., *Deleavey, G. F., Owen, S. C., Damha, M. J., Shoichet, M. S. Click Conjugated Polymeric Immuno-Nanoparticles for Targeted siRNA and Antisense Oligonucleotide Delivery. Biomaterials. 34(33), 8408–8415 (2013).
  • Martín-Pintado, N., Yahyaee-Anzahaee, M., Deleavey, G. F., Portella, G., Orozco, M., Damha, M. J., Gonzalez, C. Dramatic Effect of Furanose C2′ Substitution on Structure and Stability: Directing the Folding of the Human Telomeric Quadruplex with a Single Fluorine Atom. J. Am. Chem. Soc. 135, 5344–5347 (2013).
  • Deleavey, G. F., Frank, F., Hassler, M., Wisnovsky, S., Nagar, B., Damha, M. J. The 5′ binding MID domain of human Argonaute2 tolerates chemically modified nucleotide analogues. Nucleic Acid Ther. 23, 81–87 (2013).
  • Souleimanian, N., Deleavey, G. F., Soifer, H., Wang, S., Tiemann, K., Damha, M. J., Stein, C. A. Antisense 2′-Deoxy, 2′-Fluoroarabino Nucleic Acid (2′F-ANA) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids. Mol Ther Nucleic Acids 1, e43 (2012).
  • Felber, A. E., Bayo-Puxan, N., Deleavey, G. F., Castagner, B., Damha, M. J., Leroux, J. C. The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity. Biomaterials 33, 5955–5965 (2012).
  • Deleavey, G. F. & Damha, M. J. Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing. Chemistry & Biology 19, 937–954 (2012).
  • Wahba, A. S., Azizi, F., Deleavey, G. F., Brown, C., Robert, F., Carrier, M., Kalota, A., Gewirtz, A. M., Pelletier, J., Hudson, R. H. E., Damha, M. J. Phenylpyrrolocytosine as an unobtrusive base modification for monitoring activity and cellular trafficking of siRNA. ACS Chem. Biol. 6, 912–919 (2011).
  • Felber, A. E., Castagner, B., Elsabahy, M., Deleavey, G. F., Damha, M. J., Leroux, J. C. siRNA nanocarriers based on methacrylic acid copolymers. J Control Release 152, 159–167 (2011).
  • Gagnon, K. T., Pendergraff, H. M., Deleavey, G. F., et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166–10178 (2010).
  • *Deleavey, G. F., *Watts, J. K., Alain, T., Robert, F., Kalota, A., Aishwarya, V., Pelletier, J., Gewirtz, A. M., Sonenberg, N., Damha, M. J. Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res. 38, 4547–4557 (2010).
  • Elsabahy, M., Wazen, N., Bayo-Puxan, N., Deleavey, G. F., Servant, M., Damha, M. J., Leroux, J. C. Delivery of Nucleic Acids through the Controlled Disassembly of Multifunctional Nanocomplexes. Adv. Funct. Mater. 19, 3862–3867 (2009).
  • Deleavey, G. F., Watts, J. K. & Damha, M. J. in Current Protocols in Nucleic Acids Chemistry (eds. Beaucage, S. L., Bergstrom, D. E., Herdewijn, P. & Matsuda, A.). 16.3.1–16.3.22 (Hoboken, NJ: John Wiley & Sons, Inc., 2009).
  • Watts, J. K., Deleavey, G. F. & Damha, M. J. Chemically modified siRNA: tools and applications. Drug Discov. Today 13, 842–855 (2008).
  • Joseph Harriman, D., Deleavey, G. F., Lambropoulos, A., Deslongchamps, G. Reverse-docking study of the organocatalyzed asymmetric Strecker hydrocyanation of aldimines and ketimines. Tetrahedron. 63: 13032–13038 (2007).

 PATENT APPLICATIONS:

  • Petrecca, K., Damha, M. J., Deleavey, G. F. (2011) Method for Reducing Expression of Downregulated in Renal Cell Carcinoma in Malignant Gliomas. WO2011143762.
  • Damha, M. J., Watts, J. K., Deleavey, G. F. (2009) Oligonucleotide Duplexes Comprising DNA-like and RNA-like Nucleotides and Uses Thereof. WO2009146556.
  • Sonenberg, N., Costa-Mattioli, M., Colina Munoz, H. R., Svitkin, I. V., Alain, T., Damha, M. J., Deleavey, G. F. (2008) Immune Response Modulation and Uses Thereof. WO2009076775.

* joint first authorship.